Dec 19, 2014--Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation , today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for continuous oral treatment with REVLIMID R in adult patients with previously untreated multiple myeloma who are not eligible for stem cell transplantation. The CHMP reviews applications for all 28 member states in the European Union , as well as Norway, Liechtenstein and Iceland.
http://ift.tt/1zIQSCd
http://ift.tt/1zIQSCd
No comments:
Post a Comment